Currently, TPO-RAs, romiplostim, eltrombopag, avatrombopag, and lusutrombopag have been approved by the FDA and European Medicines Agency (EMA) to increase platelet counts in a variety of conditions, such as immune thrombocytopenia (ITP) and severe aplastic anemia [23]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.